Monobody Based Therapeutic Drugs Market

Monobody Based Therapeutic Drugs Market - Global
Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Monobodies are synthetic binding proteins in which fibronectin type III domain (FN3) is used as
a molecular scaffold. Monobodies are robust alternative to antibodies to create target-binding
proteins. The term monobody was devised by Koide group in 1998. Monobody belong to a class
called antibody mimics aiming to overcome the shortcomings of natural antibody. A major
advantage of monobody is that it can be used as genetically encoded intracellular inhibitors.
Adnexus (now a part of Bristol-Myers Squibb), uses monobody technology to inhibit tumor
angiogenesis since 2007.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/43
Monobody – a technology with great potential in Cancer Treatment
Monobody is a technology which has great potential in the treatment of cancer. Monobody is
independent of their environment and can be used as genetically encoded inhibitors. When a
monobody binds to a protein then it work as an inhibitor of that protein.
Pegdinetanib, also known as Adnectin, is an antagonist of vascular endothelial growth factor
receptor 2 has entered in clinical trial II for the treatment of glioblastoma. Adnectins is based
on 10th fibronectin type III domain designed to bind with high affinity and specificity to
relevant targets. There are three solvent accessible loops (BC, DE, and FG) which are
responsible for binding. Various monobody proteins have been developed for clinical efficacy
against cancer and infections. The market of monobody will be high in developed region like
America because of availability of advance medical technology, good medical facilities and
medical infrastructure.
Success of therapeutic antibodies has sparked a growing interest to create molecules that bind
to the target molecule specifically and efficiently. A common alternative process is that the
libraries of monobody being constructed which can be obtained by capturing natural diversity
of an antibody.
Research in the field of Monobody
Researchers at the University of Illinois, Chicago identified a monobody, NS1, which can block
oncogene activity. 30% of all cancers are due to RAS mutation. RAS mutation is also found in
90% of pancreatic cancers and frequently occurs in colon cancer, lung cancer and melanoma.
The NS1 monobody bind to RAS protein molecule and inhibits its oncogenic activity.
Monobody – a better alternative
Antibodies are successful tools used in diagnostics, purification, and therapeutics. Antibodies
have their limitations also like high product cost and low stability. Alternative tools based on
nucleic acid (aptamers), polypeptides (engineered binding proteins) and inorganic matrices have
received attention recently. With increasing research activities for drug development in cancer,
more information would be gathered with respect to monobodies too. Because of high
specificity and affinity monobodies have potential and can be used in organ transplant in near
future and can affect the antibodies market. Successful outcomes will boost investors to develop
this technology and address the unmet need of cancer patients undergoing antibody therapy.
Use of monobodies as therapeutic drug improves patient situation and hence companies are
striving to develop monobodies to be used as therapeutic drugs in the treatment of cancer.
Report includes chapters which deeply display the following deliverable about industry :
• Monobody Based Therapeutic Drugs Market Research Objective and Assumption
• Monobody Based Therapeutic Drugs Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Monobody Based Therapeutic Drugs Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Monobody Based Therapeutic Drugs Market, By Regions
• Monobody Based Therapeutic Drugs Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Monobody Based Therapeutic Drugs Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Monobody Based Therapeutic Drugs Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Monobody Based Therapeutic Drugs Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Introduction of monobody will have a major impact in developed regions
The rate of organ transplantation in the U.S. is high. According to National Kidney Foundation,
there are currently 121,678 people waiting for organ transplant in the U.S of which 100,791
await kidney transplant. Monoclonal antibodies are used in successful transplant and are
administered before transplant. It will become one of the major drivers for monobody based
therapeutic drugs market. Monobody technology requires high investment to commercialize. The
advancement of monobody technology to treat cancer will have an impact on the existing
antibody treatment technologies.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/43
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Monobodies are synthetic binding proteins in which fibronectin type III domain (FN3) is used as a molecular scaffold.

Download Report